Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Androgens, diabetes and prostate cancer.

Grossmann M, Wittert G.

Endocr Relat Cancer. 2012 Sep 5;19(5):F47-62. doi: 10.1530/ERC-12-0067. Print 2012 Oct. Review.

PMID:
22514110
[PubMed - indexed for MEDLINE]
Free Article
2.

Androgen action in the prostate gland.

Yadav N, Heemers HV.

Minerva Urol Nefrol. 2012 Mar;64(1):35-49. Review.

PMID:
22402316
[PubMed - indexed for MEDLINE]
3.

Obesity, metabolic syndrome, and prostate cancer.

Hsing AW, Sakoda LC, Chua S Jr.

Am J Clin Nutr. 2007 Sep;86(3):s843-57. Review.

PMID:
18265478
[PubMed - indexed for MEDLINE]
Free Article
4.

Testosterone and prostate cancer: revisiting old paradigms.

Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C.

Eur Urol. 2009 Jul;56(1):48-56. doi: 10.1016/j.eururo.2009.03.088. Epub 2009 Apr 8. Review.

PMID:
19375844
[PubMed - indexed for MEDLINE]
5.

Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome.

Yu IC, Lin HY, Sparks JD, Yeh S, Chang C.

Diabetes. 2014 Oct;63(10):3180-8. doi: 10.2337/db13-1505. Review.

PMID:
25249645
[PubMed - indexed for MEDLINE]
6.

The role of androgens and the androgen receptor in prostate cancer.

Debes JD, Tindall DJ.

Cancer Lett. 2002 Dec 10;187(1-2):1-7. Review.

PMID:
12359344
[PubMed - indexed for MEDLINE]
7.

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ.

Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Review.

PMID:
19025432
[PubMed - indexed for MEDLINE]
8.

Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.

Carruba G.

J Cell Biochem. 2007 Nov 1;102(4):899-911. Review.

PMID:
17786930
[PubMed - indexed for MEDLINE]
9.

Androgen deficiency, diabetes, and the metabolic syndrome in men.

Kalyani RR, Dobs AS.

Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):226-34. Review.

PMID:
17940444
[PubMed - indexed for MEDLINE]
10.

Implications of insulin-like growth factor-I for prostate cancer therapies.

Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y.

Int J Urol. 2009 Feb;16(2):161-7. doi: 10.1111/j.1442-2042.2008.02224.x. Epub 2008 Dec 5. Review.

PMID:
19183230
[PubMed - indexed for MEDLINE]
11.

Metabolic and cardiovascular effects of androgen deprivation therapy.

Hakimian P, Blute M Jr, Kashanian J, Chan S, Silver D, Shabsigh R.

BJU Int. 2008 Dec;102(11):1509-14. doi: 10.1111/j.1464-410X.2008.07933.x. Epub 2008 Aug 22. Review.

PMID:
18727614
[PubMed - indexed for MEDLINE]
12.

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.

Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS.

Cancer. 2006 Feb 1;106(3):581-8.

PMID:
16388523
[PubMed - indexed for MEDLINE]
Free Article
13.

Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence.

Astorg P.

Cancer Causes Control. 2004 May;15(4):367-86. Review.

PMID:
15141138
[PubMed - indexed for MEDLINE]
14.

Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

Shiota M, Yokomizo A, Naito S.

Free Radic Biol Med. 2011 Oct 1;51(7):1320-8. doi: 10.1016/j.freeradbiomed.2011.07.011. Epub 2011 Jul 23. Review.

PMID:
21820046
[PubMed - indexed for MEDLINE]
15.

Prevention of hormone-related cancers: prostate cancer.

Parnes HL, Thompson IM, Ford LG.

J Clin Oncol. 2005 Jan 10;23(2):368-77. Review.

PMID:
15637399
[PubMed - indexed for MEDLINE]
16.

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME.

Cancer Res. 2004 Dec 1;64(23):8620-9.

PMID:
15574769
[PubMed - indexed for MEDLINE]
Free Article
17.

Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling.

Williams G.

Mol Cell Endocrinol. 2012 Apr 4;351(2):269-78. doi: 10.1016/j.mce.2011.12.017. Epub 2012 Jan 5.

PMID:
22233684
[PubMed - indexed for MEDLINE]
18.

Metabolic syndrome, androgens, and hypertension.

Moulana M, Lima R, Reckelhoff JF.

Curr Hypertens Rep. 2011 Apr;13(2):158-62. doi: 10.1007/s11906-011-0184-0. Review.

PMID:
21274756
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action.

Carruthers M.

J Sex Med. 2008 Apr;5(4):998-1012. doi: 10.1111/j.1743-6109.2007.00721.x. Epub 2008 Jan 21. Review.

PMID:
18221290
[PubMed - indexed for MEDLINE]
20.

Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.

Fukushima H, Masuda H, Kawakami S, Ito M, Sakura M, Numao N, Koga F, Saito K, Fujii Y, Yamamoto S, Yonese J, Fukui I, Kihara K.

Urology. 2012 Jun;79(6):1329-34. doi: 10.1016/j.urology.2012.01.070.

PMID:
22656412
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk